SFTPA1 variant carriers are at increased risk of inherited lung disease (Benusiglio et al., 2021), and this gene may be a viable prognostic biomarker since it is connected to immune cell infiltration and the effectiveness of immunotherapy in lung cancer (Yuan et al., 2022). Here, SFTPA1 is linked to lung carcinoma.